BLTE · Belite Bio, Inc
$157.01
+0.32 (+0.20%)
At close · Aug 27
Market Cap
$6.30B
Shares
40.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$157.01
Open$156.69
Day$154.02–158.15
52W close$63.03–190.30
Avg vol 30d171K
Short int1.1M · 2.8% float · 5.8d
Short vol71%
Last earningsAug 13, 2026
DataApr 2022–Aug 2026
Up next
Next earnings call
Dec 7, 2026
Est · unconfirmed
· in 14 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+0%
above
Price vs 50-day avg
+1%
above
RSI (14)
46
neutral
MACD trend
Negative
52-week position
74%
mid-range
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−9%
trailing
YTD return
−2%
this year
Relative strength
−24%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $156 › 200d $156 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$2.9M over 90 days · 100% sells
Short interest
Falling
2.77% of float · ▼ -1.6% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
81 holders — near 3-yr high, broad support
Squeeze score
56
elevated · 0–100
Fundamentals
EPS growth
−96%
Y/Y
Free cash flow
$-37.1M
Balance sheet
$352.9M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
R&D-related activity costs
· next three years
$150M
Commercialization costs
· next three years
$200M – $250M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+0%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
74%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $156 › 200d $156 — 200d above 50d
Institutional flow
Accumulating
+8% holders QoQ · +22 funds added
Insider flow
Distributing
Net -$2.9M over 90 days · 100% sells
Short interest
Falling
2.77% of float · ▼ -1.6% MoM · 5.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
81 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $63
Now $157 · 74%
Range high $190
vs 200-day avg +0%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLTE
this stock
Belite Bio, Inc
|
$6.30B | -1.8% | — | — | 2.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +4.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLTE | -3.0% | -1.8% | -9.4% | -1.0% | -1.8% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -4.2% | -5.8% | -24.1% | -4.2% | -14.9% |
Key facts
CIK
1889109
CUSIP
07782B104
13F (30d)
72 filings
72 filers
Visit website
Investor relations